CCR5 and graft versus host disease: Remarkably, the small occurrence of acute and chronic GVHD observed in patients that received CBD was analogous to the occurrence of GVHD reported in phase I/II studies on subjects treated with new drugs such as maraviroc (CCR5 antagonist), bortezomib, and vorinostat [190,191,192].